Clinical Trials Browser

Phase 2 × patritumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Phase 2 Terminated

87 enrolled 13 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site